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Abstract
Objective: Clinical stages in amyotrophic lateral sclerosis (ALS) can be measured using a simple system based on the number
of CNS regions involved and requirement for gastrostomy or noninvasive ventilation (NIV). We aimed to design a standard
operating procedure (SOP) to define the standardized use and application of the King’s staging system. Methods: We
designed a SOP for the King’s staging system. We wrote case vignettes representative of ALS patients at different disease
stages. During two workshops, we taught health care professionals how to use the SOP, then asked them to stage the
vignettes using the SOP. We measured the extent to which SOP staging corresponded with correct clinical stage. Results:
The reliability of staging using the SOP was excellent, with a Spearman’s Rank coefficient of 0.95 (p<0.001), and was high
for different groups of health care professionals, and for those with different levels of experience in ALS. The limits of agree-
ment between SOP staging and actual clinical stage lie within a single stage, confirming that there is a clinically acceptable
level of agreement between staging using the SOP and actual King’s clinical stage. There were also no systematic biases of
the SOP over the range of stages, either for over-staging or under-staging. Conclusions: We have demonstrated that the stag-
ing SOP provides a reliable method of calculating clinical stages in ALS patients and can be used prospectively by a range
of health care professionals with different levels of experience, as for example may be the case in multicentre clinical trials.
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Introduction
Amyotrophic lateral sclerosis (ALS) is progressive
neurodegenerative disease affecting upper and lower
motor neurons. Two recent staging systems have
been proposed to measure the clinical progression of
disease (1,2). The King’s staging system consists of
five disease stages, with Stage 5 being death. Stages
1–3 are based upon the number of El Escorial cen-
tral nervous system (CNS) regions involved in the
disease, measured by weakness, wasting, spasticity,
dysphagia, or dysarthria. Stage 4 is nutritional fail-
ure, defined by the requirement for gastrostomy, or
respiratory failure, defined by the requirement for
noninvasive ventilation (NIV), and based upon the
National Institute for Clinical Excellence MND
Guidelines (Supplemental Material). The
Milano–Torino (MiToS) Staging system comprises
six stages, based on functional impairment as
assessed by the revised ALS Functional Rating Scale
(ALSFRS-R) (2). These staging systems are comple-
mentary, with the King’s clinical staging system
closely linked to anatomical spread, and the MiToS
system closely tracking functional spread. As a result,
King’s clinical staging has a higher resolution in
early-mid diseases stages and the MiToS system in
late disease stages (3). In the King’s staging system,
there is more homogeneity between patients in the
same stage, and a greater discrimination between
patients in different disease stages (4).
In ALS, these staging systems correlate with a
decline in functional measures, health utility and
quality of life scores, and an increase in
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socioeconomic costs, comprising costs of health-
care, and loss of productivity (2,5–7). ALS stages
have validity as meaningful outcome measures in
ALS clinical trials, as they help to account for the
inherent heterogeneity in patient populations, and
can facilitate the development of drugs which dif-
fering efficacies throughout disease progression
(8,9). Progression to a higher ALS disease stage is
now being utilized as a primary outcome measure
in Phase II randomized controlled trial (10) and
has been used to determine the stage at which
Riluzole prolongs survival in ALS in a retrospect-
ive study (11). Staging can be used to select
patients for clinical studies, for example investigat-
ing neuroimaging biomarkers in early disease
stages (12). Furthermore, staging has utility in
mapping to neuroimaging and biochemical bio-
markers in ALS patients, correlating with reduction
in white matter integrity in ALS patients with
repeat expansions in the C9orf72 gene on neuroi-
maging (13), and with higher levels of CSF neurofi-
lament light chain (14,15). Staging correlates with
other important disease parameters, including sus-
tained and forced vital capacity (7), and energy
expenditure (16). Mitochondrial dysfunction is
involved in the pathogenesis of ALS (17), and mito-
chondrial activity detected in patient peripheral
blood mononuclear cells decreases with increasing
disease stage (18), indicating that staging may cor-
relate with underlying etiopathogenic mechanis-
tic markers.
ALS is on a clinical, genetic and pathological
spectrum with frontotemporal dementia (FTD).
Up to 15% of people with ALS have a diagnosis of
FTD, and cognitive impairment occurs in about
50% of people with ALS (19,20). Measures of
behavior and cognition are reduced in later ALS
disease stages (21–23). Moreover, specific staging
systems to measure the extent of cognitive involve-
ment in ALS have been developed (24,25) and
could be used in parallel with ALS disease stag-
ing systems.
We have previously shown that King’s clinical
stages can be reliably estimated retrospectively in
preexisting datasets from the ALSFRS-R (26). In
order for the King’s staging system to be applied
by different health care professionals of varying
levels of experience working in ALS, as for
example may be the case in a multicentre clinical
trial, we designed a standard operating procedure
(SOP) for the use of the King’s system. We then
investigated whether it could be used by a variety
of health care professionals.
Materials and methods
We wrote a SOP for using the King’s clinical stag-
ing system for ALS (1) (Supplementary Material).
We created 17 case vignettes of patients with ALS,
representing a spectrum of cases with different
stages of disease, ranging from Stage 1–4
(Supplementary Material). In 2016 and 2017, we
ran two staging workshops during the European
Network for the Cure of ALS (ENCALS) meet-
ings. Participants included doctors, nurses, allied
health care professionals, and researchers with
varying lengths of experience in ALS. We collected
data on each participant’s occupation and length
of time working in ALS. During each workshop,
we provided training in how to apply the staging
SOP, and asked participants to stage the vignettes
using the SOP. In the first workshop, all 17
vignettes were included in the study, and in the
second workshop 10 of the vignettes
were included.
Statistical analysis
To measure the reliability of staging using the
SOP across the entire cohort, we calculated a
Spearman’s rank correlation coefficient between
the actual King’s clinical stage and the King’s
stage assessed according to the SOP. We also cal-
culated Spearman’s rank correlation coefficients
for different health care professional groups
included in the study (doctors, nurses, and allied
health care professionals), and for those with less
than 10 years, or 10 years or greater experience
working in ALS.
As a further step to investigate the reliability of
using the SOP to calculate clinical stage, we used
the Bland–Altman method to calculate the differ-
ence between actual King’s clinical stage and
King’s stage calculated by participants using the
SOP, and the mean of the correct clinical stage
and stage using the SOP, determining the limits of
agreement between these (27,28). To test for any
systematic bias in the SOP, leading to over-estima-
tion or under-estimation of stage, we calculated
the Spearman’s rank correlation coefficient
between the difference between actual King’s clin-
ical stage and stage using the SOP, and also the
mean of the actual King’s clinical stage and stage
using the SOP (28).
Analyses were performed in SPSS version 20.0
(SPSS Inc., Chicago, IL) and GraphPad Prism
version 6.07 (GraphPad Software, La Jolla, CA).
Results
The study consisted of 61 participants in total,
with doctors (65.5%), nurses (9.1%), and other
allied health care professionals (25.5%) repre-
sented in the cohort (Figure 1(A)). There was an
even distribution between those with less than 10
years’ experience working in ALS (50.8%) and
those with 10 years’ or greater experience (48.2%)
(Figure 1(B)).
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Use of a standard operating procedure leads to reliable
clinical staging
Across the cohort, we found that use of a SOP led
to a high reliability of clinical staging of vignettes.
The correlation between staging of the clinical
vignettes using the SOP and the actual King’s clin-
ical stage was Spearman’s rho = 0.95, p<0.001
(Figure 2). There was a very strong correlation
between staging using the SOP and the actual
King’s clinical stage for every health care profes-
sional group, with similar correlations between
each group: doctors (Spearman’s rho = 0.95,
p<0.001), nurses (Spearman’s rho = 0.93,
p<0.001), and allied health care professionals
(Spearman’s rho = 0.94, p< 0.001). The correl-
ation between staging using the SOP and the
actual King’s clinical stage was the same for those
with at least 10 years’ experience working with
patients with ALS (Spearman’s rho = 0.95,
p<0.001) as for those with less than 10 years’
experience (Spearman’s rho = 0.95, p<0.001).
Overall, most participants correctly staged case
vignettes in Stages 1 (95.9%), 2 (95.7%), 3
(84.6%), and 4 (98.9%) using the SOP (Figure 2).
We used the Bland–Altman method to calcu-
late the difference between correct clinical stage
and stage using the SOP for all pairs and the mean
of the stages for all pairs. The mean of the differ-
ence in stage between the two methods was 0.01
(95% CI of the mean 0.01–0.04, standard devi-
ation 0.35) with the 95% confidence limits of
agreement lying between 0.69 and 0.71.
Therefore, the limits of agreement lie within a sin-
gle stage, confirming that there is a clinically
acceptable level of agreement between staging
using the SOP and actual King’s clinical stage. To
test for systematic bias of the SOP over the range
of stages, leading to over-staging or under-staging,
we calculated a Spearman’s rank correlation coeffi-
cient between the differences in stages and the
means of stages, which showed a negligible rela-
tionship between the two (Spearman’s rho =
0.069, p¼ 0.05). Therefore, there are unlikely to
be any systematic biases in staging when using the
SOP. As a further confirmation of this, there was a
similar number of cases where staging using the
SOP led to a higher stage than the actual clinical
stage (23 cases) and cases where SOP staging led
to a lower stage (20 cases), and these erroneously
staged cases amounted to only 5.35% in total of
the whole study.
Use of the standard operating procedure for patients
with stage 4 disease
Variability in the answers for staging using the SOP
was greatest for vignettes 8, 9, and 12 (Figure 3).
In vignette 9, a gastrostomy had been inserted for a
reason other than ALS, due to oropharyngeal
malignancy. Some participants had staged this case
as Stage 4, despite the gastrostomy not being
required as an intervention for ALS-related dyspha-
gia. The SOP clarifies that when the gastrostomy is
required as an intervention for ALS-related dyspha-
gia, Stage 4 is reached and has clear parameters for
when these criteria are fulfilled. In vignettes 8 and
12, the patients did not yet meet the criteria for
respiratory failure; however, some participants had
staged these cases as Stage 4. The SOP clarifies
that Stage 4 is only reached when the UK National
Institute of Health and Care Excellence MND
guidelines for respiratory failure are reached, and
the guidelines are stated in a summarized format
within the SOP, although relaxed, country-specific
guidelines are also acceptable. Furthermore, the
average staging for vignette 3 across the participants
was 2.8, demonstrating that it was relatively under-
staged, as the correct answer for this vignette was
Stage 3. This is likely due to some participants not
classifying a brisk jaw jerk on examination, without
evidence of dysarthria or dysphagia, as indicative of
brainstem involvement. However, we have clarified
in the SOP that this sign does indicate brain-
stem disease.
Discussion
We have shown that using an SOP provides a
highly reliable method of calculating clinical stages
Figure 1. Demographics of participants included in the study. (A) The study consisted of 61 participants in total, with doctors
(65.5%), nurses (9.1%), and allied health care professionals (25.5%) represented in the cohort. (B) There was an even distribution
between those with less than 10 years’ experience working in ALS (50.8%) and those with 10 years’ or greater experience (48.2%).
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in patients with ALS. The 95% confidence limits
of agreement of staging using the SOP were within
less than a clinical stage and there were no clear
systematic biases leading to over- or under-staging,
further confirming that using the SOP for clinical
staging is reliable.
We have demonstrated that using an SOP is
effective across different groups of health care pro-
fessionals and across different levels of experience
working within ALS. ALS staging systems have
utility in stratifying patients in clinical studies, as a
marker of disease progression when assessing valid-
ity of biomarkers, and as outcome measures in
clinical trials. For their use to be effective, it is
critical the system is simple to understand and
apply. This is of clear importance in ensuring stag-
ing can be applied reliably by different individuals,
separated in space and time, as is the case, for
example in multicentre clinical trials. Participants
were attendees at an ALS specialist meeting,
therefore, are likely to be representative of the
individuals that would use the SOP and staging
system in the future in clinical studies and clinical
trials. The impact of this study is that the SOP can
now be implemented widely in future studies
where it would be useful to prospectively collect
staging data.
We found that the vignettes that were most
variable were sometimes over-estimated as Stage 4.
We have clarified in the SOP the exact definitions
of when Stage 4 is reached, either when gastros-
tomy or NIV are required. It is likely that as this
SOP is used more frequently alongside further
training sessions, its repeated use will improve the
reliability of clinical staging further. Some flexibil-
ity in the definitions of Stage 4 may, however, be
necessary for implementations in different
health systems.
Although the agreement between staging using
the SOP and actual King’s clinical stage was high,
it was not perfect. However, we found that the
limits of agreement lay within a single stage, with
systematic biases being negligible, and we detected
a very low rate of errors (5%) represented
equally by cases of over- and under-staging, indi-
cating that the extent of agreement is clinically
acceptable. Overall, this suggests that the SOP is
straightforward to understand as written.
A potential limitation of this study is that stag-
ing using the SOP was performed directly after a
training session was delivered, and the accuracy of
staging may have, therefore, been at its highest at
this time. However, we would expect these reliabil-
ity measures to continue to improve after repeated
use of the SOP on subsequent occasions, and the
SOP is now readily available for users to refer to
in the future as required. A further limitation is
that this cohort represents a relatively small
Figure 2. Use of a standard operating procedure leads to reliable clinical staging. Participants were trained in how to use the staging
standard operating procedure (SOP, Supplementary Material), and most correctly staged case vignettes using the SOP. The numbers to
the right of each bubble represent the number of answers within each group.
Figure 3. Variability of scores for staging using the SOP for
each case vignette. Bars represent the mean and standard
deviation of scores for staging using the SOP for each vignette.
Variability in the answers was greatest for vignettes 8, 9, and 12.
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number of participants with an overrepresentation
of doctors compared to nurses and other allied
health care professionals. Further studies are,
therefore, required to validate whether the SOP is
reliable across a larger and more diverse group of
health care professionals. Future validation could
be achieved using an online survey platform.
In conclusion, here we have presented a SOP
for the application of the King’s clinical staging
system for ALS. This SOP makes staging reliable
and simple to apply to a variety of representative
patient cases, and by a range of health care profes-
sionals with different levels of experience in ALS.
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